22 RESULTS
Go to another page:
COMMENT The finding of increased brain-derived tau in the blood plasma or serum is an important advance and helps resolve why total tau in the periphery wasn’t previously specific for Alzheimer’s disease. This study adds to the growing knowledge of blood biomarke
COMMENT The finding of increased brain-derived tau in the blood plasma or serum is an important advance and helps resolve why total tau in the periphery wasn’t previously specific for Alzheimer’s disease. This study adds to the growing knowledge of blood biomarke
COMMENT Jucker and colleagues again make an important contribution to our understanding of the mechanisms of AD, and the relationships between amyloid and tau. Their results clearly indicate that amyloid is sufficient for p-tau217 and p-tau181 and, together with
COMMENT This work by Tom Montine’s group is incredible in the spatial resolution and identification of protein amounts and co-localization at the synapse in AD. It offers a new orthogonal window to peer into the molecular machinery of AD (and synapses in general)
COMMENT Plasma AB-First Sign of AD, but Tough to Measure Prospectively? At C 2 N Diagnostics (St. Louis, Missouri), we were very pleased to see at this year’s CTAD meeting the excellent progress being made in the field to incorporate blood-based biomarkers (BBBs)
COMMENT We would like to thank Dr. Marcel Verbeek for a thorough review of our manuscript and data. We believe that one important finding of our study is the consistency in the plasma Aβ42/Aβ40 ratio data (Table 1 and Table 3 in the published paper) between the B
COMMENT Plasma p-tau231 is a welcome measure in the growing list of highly specific blood-based measures. The comprehensive analysis to amyloid and tau PET as well as CSF and neuropathology are great strengths of this study, as are the number of cohorts evaluated
COMMENT The paper by Palmqvist et al. on blood plasma phospho-tau 217 is a remarkable clinical study clearly demonstrating the value of phospho-tau 217 for identifying AD pathology. These findings advance our understanding of how p-tau217 is related to amyloid an
COMMENT Q&A with Randall Bateman of Washington University School of Medicine Q: Compared with February, how are you feeling now about this trial? A: I am excited. We are on the right track in terms of impacting the biology of the disease. We couldn’t make a c
COMMENT Q: What are your thoughts about the wisdom of futility analyses in AD trials, given what our field is learning about exposure and response times in AD treatment? Futility analyses are complex and depend on the specific circumstances and how they are desig
COMMENT The field is clearly moving forward with the ability of a fourth drug to remove amyloid to a normal level, as measured by PET. Now with aducanumab, gantenerumab, and n3pg, BAN2401 has demonstrated reversal of amyloid plaques to normal levels, representing
COMMENT The data presented provides another important and interesting advance in understanding the relationship between biomarkers and potential cognitive changes in Alzheimer’s disease. The authors nicely demonstrated dose dependent biomarker effects on soluble
COMMENT The test of BACE inhibition at earlier stages of AD, such as this study in prodromal AD, and earlier-stage prevention efforts, is necessary for the field. Merck did an outstanding job of running top-notch trials to help address the question in prodromal t
COMMENT The work by Peters et. al is beautiful and comprehensive in quantitation of plaque growth and formation. They clearly demonstrated better efficacy of the β-secretase inhibitor before individual plaque formation, suggesting that treating during a period of
COMMENT The authors should be congratulated on developing a highly specific blood test for amyloidosis and demonstrating it so well. It was a fantastic paper that found nearly identical results in performance of a mass spectrometry-based blood test for amyloid pl
Go to another page:
